111 related articles for article (PubMed ID: 12494768)
41. [Inhibiton of breast cancer MCF-7 cells proliferation by c-myc expression of liposome-mediated antisense oligonucleotide].
Zhang LJ; Shui QL; Zhao XP
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2005 Aug; 21(3):338-9, 355. PubMed ID: 21162214
[No Abstract] [Full Text] [Related]
42. Structural determinants for alternative splicing regulation of the MAPT pre-mRNA.
Lisowiec J; Magner D; Kierzek E; Lenartowicz E; Kierzek R
RNA Biol; 2015; 12(3):330-42. PubMed ID: 25826665
[TBL] [Abstract][Full Text] [Related]
43. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
44. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
[TBL] [Abstract][Full Text] [Related]
45. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
46. Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition.
Inagaki M; Togawa K; Carr BI; Ghosh K; Cohen JS
Transplant Proc; 1992 Dec; 24(6):2971-2. PubMed ID: 1334602
[TBL] [Abstract][Full Text] [Related]
47. [Effect of phosphorothioate antisense Bcl-xL oligodeoxynucleotides on apoptosis and thermosensitivity of BcaCD885 cells].
He YW; Bian L; Liang XH
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Apr; 22(2):112-4. PubMed ID: 15190790
[TBL] [Abstract][Full Text] [Related]
48. Molecular mechanisms of action of antisense drugs.
Crooke ST
Biochim Biophys Acta; 1999 Dec; 1489(1):31-44. PubMed ID: 10806995
[TBL] [Abstract][Full Text] [Related]
49. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
50. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
[TBL] [Abstract][Full Text] [Related]
51. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
52. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
53. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
54. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
55. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
Delihas N
Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
[TBL] [Abstract][Full Text] [Related]
56. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene.
Degols G; Leonetti JP; Mechti N; Lebleu B
Nucleic Acids Res; 1991 Feb; 19(4):945-8. PubMed ID: 1708128
[TBL] [Abstract][Full Text] [Related]
57. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Nichols GL; Stein CA
Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
[TBL] [Abstract][Full Text] [Related]
58. Targeted delivery of antisense oligonucleotides in cancer.
Pastorino F; Stuart D; Ponzoni M; Allen TM
J Control Release; 2001 Jul; 74(1-3):69-75. PubMed ID: 11489484
[TBL] [Abstract][Full Text] [Related]
59. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.
Koh CM; Bezzi M; Low DH; Ang WX; Teo SX; Gay FP; Al-Haddawi M; Tan SY; Osato M; Sabò A; Amati B; Wee KB; Guccione E
Nature; 2015 Jul; 523(7558):96-100. PubMed ID: 25970242
[TBL] [Abstract][Full Text] [Related]
60. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression.
Mercatante DR; Kole R
Biochim Biophys Acta; 2002 Jul; 1587(2-3):126-32. PubMed ID: 12084454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
